| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From The First Department of Internal Medicine,*
Shinshu
University School of Medicine, Matsumoto, Mitsubishi Kagaku
BCL,
Tokyo, and Chest Disease Research
Institute,
Kyoto University, Kyoto, Japan
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Alveolar type II epithelial cells (ATII cells) have been shown to play
a key role in the maintenance of the alveolar space. ATII cells
synthesize and secrete surfactant, control the volume and composition
of the epithelial lining fluid, proliferate, and differentiate into
type I alveolar epithelial cells after lung injury to maintain the
integrity of the alveolar wall.18
Moreover, ATII cells are
located to have a role in modulating immunological activity in the
alveolar space. In this setting, ATII cell line, A549 cells secreted
monocyte chemotactic protein (MCP)-1, transforming growth factor
(TGF)-ß, and leukotriene (LT)B4 constitutively19
and
further secreted interleukin (IL)-8,15,20
IL-6,21
interferon,22
and MCP-123
in response to IL-1ß and tumor necrosis factor (TNF)-
, suggesting
participation in the intra-alveolar cytokine network.
The activation of the kallikrein-kinin system in acute lung injury has long been recognized. Bradykinin (BK) is generated from kininogens by the actions of plasma and tissue kallikreins (kininogenases).24,25 Its actions on pulmonary circulation and lung mechanics have been evaluated intensively. BK also stimulates alveolar macrophages and bronchial epithelial cells to release chemotactic factors for inflammatory cells.26,27 Recently, BKB2 antagonist attenuates the acute lung injury induced by live Pseudomonas aeruginosa infusion, including the migration of neutrophils to the lung and lung sequestration of neutrophils.28 In this context, BK may participate in the release of inflammatory mediators from lung cells.
Because the alveolar space is lined by epithelial cells, direct BK-epithelial cell contact, without intervening alveolar macrophages, is likely to occur. In the present study, we evaluated the potential of BK to stimulate ATII cells resulting in the release of inflammatory cytokines and chemokines. The results demonstrated that A549 cells released IL-6, IL-8, MCP-1, TGF-ß, and granulocyte colony-stimulating factor (G-CSF) by BK. These data suggest that BK may play roles in stimulating ATII cells and mediating inflammatory responses in the lung.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Because of difficulty in obtaining primary human type II epithelial cells of sufficient purity, A549 cells (American Type Culture Collection, Rockville, MD), from an alveolar type II cell line derived from an individual with alveolar carcinoma,29 were used. These cells retained many of the characteristics of normal type II cells such as surfactant protein, cytoplasmic multilamellar inclusion bodies, and cuboidal appearance and had been extensively used to assess type II pneumocyte effecter cell functions.15,21,28 A549 cells were grown as monolayers on 100-mm tissue culture dishes with supplemented F-12 medium as previously reported.19 The cells from monolayers were harvested with trypsin (0.25%) and EDTA (0.1%) in PBS, centrifuged at low speed (250 x g for 5 minutes), and resuspended in fresh medium at the concentration of 1.0 x 106 cells/ml in 35-mm tissue culture dishes. The cells were grown to confluence on the dish during 5 to 7 days. After the cell reached confluence, the cells were used for the experiment.
Measurement of BK Concentration in A549 Cell Culture
We measured the concentration of BK at the selected time points (12, 14, 48, and 72 hours) to decide the exposure period of A549 cells to BK and determined the levels of BK in the supernatant fluids to estimate the half-life of BK. BK was measured by a highly sensitive radioimmunoassay as previously reported.30
Exposure of A549 Cells to Bradykinin
Medium was removed from cells by washing twice with serum-free F-12, and cells were incubated with F-12 without fetal calf serum in the presence or absence of BK (0, 0.1, 1.0, 10, and 100 µmol/L; Sigma Chemical Co., St. Louis, MO) and cultured for 12, 24, 48, 72, and 96 hours. BK did not cause A549 cell injury (no deformity of cell shape and no detachment from tissue culture dish, and greater than 95% of cells were viable by trypan blue exclusion) after a 72-hour incubation at the maximal doses. The culture supernatant fluids were harvested and frozen at -80°C until assayed. At least seven separate A549 cell supernatant fluids were harvested from cultures for each experimental condition.
Measurement of Neutrophil and Monocyte Chemotactic Activity
Polymorphonuclear leukocytes were purified from heparinized normal human blood by the method of Böyum.31 Briefly, 15 ml of venous heparinized blood was suspended in the same volume of 3% dextran (Sigma) in isotonic saline for 30 minutes. The neutrophil-rich upper layer was aspirated and centrifuged at 400 x g for 5 minutes, and the cell pellet was resuspended in lysing solution consisting of 0.1% KHCO3 and 0.83% NH4Cl. The suspension was then centrifuged and washed three times in Hanks' balanced salt solution (HBSS; GIBCO, Gaithersburg, MD). The viability of recovered neutrophils was >98% as assessed by trypan blue and erythrosin exclusion. The cells were suspended in Gey's balanced salt solution (GIBCO) containing 2% bovine serum albumin (BSA; Sigma) at pH 7.2 to give a final concentration of 3.0 x 106 cells/ml.
Mononuclear cells were obtained for the chemotactic assay by
Ficoll-Hypaque density centrifugation (Histopaque 1077, Sigma) to
separate the red blood cells and neutrophils from mononuclear cells as
previously reported.19
The preparation routinely consisted
of 30% monocytes and 70% lymphocytes determined by morphology and
-naphthyl acetate esterase staining (Sigma) with >98% viability as
assessed by trypan blue and erythrosin exclusion. The cells were
suspended in Gey's balanced salt solution containing 2% BSA at pH 7.2
to give a final concentration of 5.0 x 106
cells/ml.
These suspensions were used in the chemotaxis assay.
The chemotaxis assay was performed in 48-well microchemotaxis chambers (Neuroprobe, Cabin John, MD) as has been described.32 The bottom wells of the chamber were filled with 25 µl of fluid containing the chemotactic stimulus. Each sample was tested in duplicate. A polycarbonate filter (Nucleopore Corp., Pleasanton, CA) with a pore size of 3 µm for neutrophil chemotaxis and 5 µm for monocyte chemotaxis was placed over the bottom wells. The silicon gasket and upper pieces of the chamber were applied, and the entire assembly was preincubated at 37°C in humidified air for 15 minutes before filling the upper wells with 50 µl of cell suspension. The chamber was incubated in humidified 5% CO2 at 37°C for 30 minutes for neutrophil assay and 90 minutes for monocyte chemotaxis. The chamber was disassembled after the incubation, and the filter was fixed, stained with Diff-Quik (American Scientific Products, McGaw Park, IL), and mounted on a glass slide. Cells that completely migrated through the filter were counted in five random high-power fields (HPF; x1000) from each duplicate well. Chemotactic response was defined as the mean number of migrated cells per HPF. F-12 without fetal calf serum was incubated identically with A549 cells, and the supernatant fluids harvested were used to determine background neutrophil and monocyte migration. Formyl-methionyl-leucyl-phenylalanine (FMLP; 10-8 mol/L in F-12; Sigma) and normal human serum that was complement activated by incubation with Escherichia coli endotoxin and diluted 10-fold with F-12 were used as positive controls for both neutrophils and monocytes.
To determine whether the migration was due to movement along a concentration gradient (chemotaxis) or stimulation to randomly migrate (chemokinesis), a checkerboard analysis33 was performed by A549 cell supernatant fluid harvested at 72 hours in response to 100 µmol/L BK. To do this, various concentrations of A549 cell supernatant fluids (1:27, 1:9, 1:3, and 1:1) were placed above the membrane with cells and below the membrane.
To ensure that monocytes, but not lymphocytes, were the primary cells
that migrated, some of membranes were stained with -naphthyl acetate
esterase according to the manufacturer's directions (Sigma).
Partial Characterization of NCA and MCA
Because NCA and MCA were detected in the A549 cell culture supernatant fluids, partial characterization of the released activity was performed using supernatant fluids harvested at 72 hours of incubation at the concentration of 100 µmol/L BK. Sensitivity to proteases was tested with trypsin treatment (final concentration, 100 µg/ml; Sigma) for 30 minutes at 37°C followed by the addition of 1.5 mol/L excess of soybean trypsin inhibitor (Sigma) to terminate the proteolytic activity before the chemotaxis assay. The lipid solubility of the activity was evaluated by mixing the A549 cell culture supernatant fluid twice with ethyl acetate, decanting the lipid phase after each extraction, evaporating the ethyl acetate to dryness, and resuspending the extracted material in F-12 used for the cell culture before the chemotaxis assay. Heat sensitivity was determined by heating the culture supernatant fluid at 98°C for 30 minutes.
Estimation of Molecular Size of the Chemotactic Activity by Column Chromatography
To determine the approximate molecular weight of the released chemotactic activity in the supernatant fluids harvested at 72 hours in response to 100 µmol/L BK, molecular sieve column chromatography was performed using Sephadex G-100 (25 x 1.25 cm; Pharmacia, Piscataway, NJ) at a flow rate of 6 ml/hour. The A549 cell culture supernatant fluid was eluted with PBS, and every fraction after the void volume was evaluated for NCA and MCA in duplicate.
Effects of Metabolic Inhibitors on the Release of NCA and MCA
Although A549 cells were capable of releasing lipoxygenase metabolites, which may account for the released NCA and MCA, the effects of nonspecific lipoxygenase inhibitors nordihydroguaiaretic acid (NDGA; 100 µmol/L; Sigma) and diethylcarbamazine (DEC; 1 mmol/L; Sigma) and 5-lipoxygenase inhibitor AA-861 (100 µmol/L; Takeda Pharmaceutical Co., Tokyo, Japan) were evaluated. The effect of the protein synthesis inhibitor cycloheximide (10 µg/ml; Sigma) was also evaluated. At these concentrations, NDGA, DEC, and AA-861 inhibited the release of LTB4 in other cell cultures in response to lipopolysaccharide and did not cause cytotoxicity to A549 cells after a 72-hour incubation.26,27
Effects of BK Receptor Antagonists for the Release of NCA and MCA
To determine the receptor responsible for the release of chemotactic activity, BKB1 receptor antagonist Des-Arg9-[Leu8]-BK (Sigma) and BKB2 receptor antagonist, D-Arg-[Hyp, 3Thi5,8,D-Phe7]-BK (Sigma), at the concentration of 100 µmol/L, were evaluated, respectively. Thirty minutes before addition of 50 µmol/L BK, A549 cells were treated with BKB1 and BKB2 receptor antagonists and incubated for 72 hours.
Effects of LTB4 and Platelet-Activating Factor Receptor Antagonists on the Released NCA and MCA
Because nonspecific lipoxygenase and 5-lipoxygenase inhibitors inhibited the release of NCA and MCA, LTB4 receptor (ONO 4057, Ono Pharmaceutical Co., Tokyo, Japan) and platelet-activating factor (PAF) receptor antagonists (TCV 309, Takeda Pharmaceutical Co., Tokyo.) at the concentration of 10-5 mol/L were used to evaluate the responsible chemotactic activity in column chromatography-separated lowest molecular weight peak in BK-induced NCA and MCA.
Measurement of LTB4 and PAF in the Supernatant Fluid
The measurement of LTB4 was performed by radioimmunoassay (RIA)19 as previously reported. Briefly, ethanol samples were centrifuged at 5500 x g at 0°C. The supernatants were evaporated under N2 gas at 37°C to cause ethanol evaporation. To each sample, 10 ml of distilled water was added. These samples were acidified to pH 4.0 with 0.1 mol/L hydrochloric acid and applied to Sep-pak C18 columns (Waters Associates, Milford, MA); the columns were washed with 10 ml of distilled water and 20 ml of petroleum ether and then eluted with 15 ml of methanol. These eluates were dried with N2 gas at 37°C and redissolved in 20 µl of methanol and 180 µl of RIA buffer (50 mmol/L Tris/HCl buffer containing 0.1% (w/v) gelatin, pH 8.6). Anti-LTB4 serum, [5,6,8,9,11,12,14,15,-3H(N)]LTB4, and synthetic LTB4 were purchased from Amersham Co. (Arlington Heights, IL). [3H]LTB4 was diluted in RIA buffer and aliquots (100 µl, containing approximately 4000 dpm) were mixed with 100 µl of standards or samples in disposable siliconized tubes. Anti-LTB4 serum diluted in RIA buffer (100 µl) and RIA buffer (100 µl) were added to give a total incubation volume of 400 µl, and the mixture was incubated at 4°C for 18 hours. Free LTB4 was adsorbed onto dextran-coated charcoal. The supernatant containing the antibody-bound LTB4 was decanted into a scintillation counter after centrifugation at 2000 x g for 15 minutes. Scintillation fluid (Aquazol 2, NEN Co., Boston, MA) was added, and radioactivity was counted by a scintillation counter (Tricarb-3255, Tackard Co., Downers Grove, IL) for 4 minutes.
PAF concentration in the supernatant fluids was measured by a scintillation proximity assay (SPA) system. This system combined the use of a high specific activity tritiated PAF tracer with an antibody specific for PAF and a PAF standard similar to the methods of measurement of LTB4.
Effects of Polyclonal Antibodies to IL-8, G-CSF, MCP-1, MIP-1,
GM-CSF, RANTES, and TGF-ß on Released NCA and MCA
The neutralizing antibodies to IL-8, G-CSF, MCP-1, RANTES,
GM-CSF, MIP-1, and TGF-ß were purchased from Genzyme (Cambridge,
MA) and were added to the A549 cell supernatant fluids, which were
harvested at 72 hours in response to 100 µmol/L BK, at the suggested
concentration to inhibit these cytokines and incubated for 30 minutes
in 37°C before chemotaxis. Then these samples were used for
chemotactic assay. The antibodies to IL-8, G-CSF, TGF-ß, and MCP-1
were tested by blocking the chemotactic response to neutrophils and
monocytes. For all antibodies, referred to the manufacturer's data for
their validity. These antibodies did not influence the chemotactic
response to endotoxin-activated serum (data not shown). For the
nonspecific effects of IgG, nonimmune IgG (Genzyme) was used as a
control antibody.
Measurement of IL-6, IL-8, G-CSF, MCP-1, MIP-1, RANTES, G-CSF,
and GM-CSF in the Supernatant Fluids
The concentrations of IL-6, IL-8, G-CSF, MCP-1, MIP-1, RANTES,
GM-CSF, and TGF-ß in A549 cell supernatant fluids cultured for 72
hours at the concentration of 100 µmol/L BK were measured by ELISA
according to manufacturers' directions. MIP-1, G-CSF, GM-CSF, and
RANTES kits were purchased from Amersham (Little Chalfont, UK), and the
minimal concentration detected by these methods was 46.9 pg/ml for
MIP-1, 31.9 pg/ml for G-CSF, 2.00 pg/ml for GM-CSF, and 15.6 pg/ml
for RANTES. IL-6, IL-8, MCP-1, and TGF-ß kits were purchased from
R&D Systems (Minneapolis, MN), and the minimal concentrations for IL-6,
IL-8, MCP-1, and TGF-ß was 0.156 pg/ml, 10.0 pg/ml, 31.3 pg/ml, and
0.31 ng/ml, respectively.
Statistics
In experiments where multiple measurements were made, differences between groups were tested for significance using one-way analysis of variance with Duncan's multiple range test applied to data at specific time and dose points. In experiments where a single measurement was made, the differences between groups were tested for significance using Student's paired t-test. In all cases, a P value less than 0.05 was considered significant. Data in figures and tables were expressed as means ± SEM.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
BK at the initial concentration of 50 µg/ml declined to 29.8 ± 1.2 µg/ml at 12 hours, 18.4 ± 0.4 µg/ml at 24 hours, 4.11 ± 0.07 µg/ml at 48 hours, and 0.137 ± 0.008 µg/ml at 72 hours (n = 3 monolayers). Thus, the half-life was ~15 hours, and the remaining level of BK after a 72-hour incubation was 0.27%. Because BK was retained in the supernatant fluids after 72 hours, the exposure of A549 cells to BK was observed after 96 hours.
Release of NCA and MCA from A549 Cells in Response to BK
A549 cells released NCA in response to BK in a dose- and
time-dependent fashion (P < 0.01, Figure 1, A and B
). The lowest concentration of BK to
stimulate A549 cells was 0.1 µmol/L. Increasing concentrations of BK
progressively increased the release of NCA up to 100 µmol/L. Although
A549 cells released a small amount of NCA constitutively, the release
of NCA began after a 12-hour exposure to BK, and the released activity
was cumulative and continued to increase even after 72 hours (Figure 1B)
.
|
). The lowest concentration of BK
examined (0.01 µmol/L) induced a substantial release of MCA.
Increasing concentrations progressively induced the release of MCA. The
release of MCA began after a 12-hour exposure to BK (Figure 2B)
. The
released activity was cumulative and increased even after 72 hours.
|
The chemotactic activities in response to FMLP and activated serum were 120.4 ± 8.7 neutrophils per HPF and 68.3 ± 3.2 monocytes per HPF and 170.6 ± 15.3 neutrophils per HPF and 75.3 ± 6.4 monocytes per HPF, respectively. BK itself in the culture medium without cells and incubated identically did not show any chemotactic activity for neutrophils and monocytes (data not shown).
Checkerboard analysis revealed that A549 cell supernatant fluids stimulated by BK induced neutrophil and monocyte migration in the presence and absence of concentration gradient across the membrane (data not shown). Thus, the migration in response to BK-stimulated A549 cell supernatant fluids was consistent with chemotactic and chemokinetic activity for both neutrophil and monocyte migration.
Partial Characterization of the Released NCA and MCA
The MCA and NCA were heterogeneous in their character. Both NCA
and MCA were partially sensitive to heat, extractable to ethyl acetate,
and digested by trypsin (Figure 3, A and B)
.
|
Incubation of A549 cells with cycloheximide inhibited the release
of both NCA and MCA (Figure 4, A and B)
.
Nonspecific lipoxygenase inhibitors NDGA and DEC and 5-lipoxygenase
inhibitor AA-861 attenuated the release of NCA and MCA in response to
100 µmol/L BK (P < 0.01; Figure 4, A and B
).
NDGA, DEC, and AA-861 did not have any effects on FMLP and
activated-serum-induced neutrophil chemotaxis (data not shown).
|
The experiments using Sephadex-100 revealed that the released NCA
was heterogeneous in size, with the estimated molecular weight at 19
kb, 81 kb, and 450 d after quinacrine (Figure 5A)
. Although A549 cells released MCA in
unstimulated supernatant fluids (Figure 5B)
, the three molecular weight
masses (25, 19, and 16 kd) before cytochrome C became prominent in
response to BK (Figure 5B)
. The addition of cycloheximide before BK
treatment inhibited the release of these high molecular weight MCAs
(data not shown).
|
The lowest molecular weight NCA and MCA separated by molecular
sieve column chromatography was inhibited by the addition of LTB4
receptor antagonist ONO 4057 ~70% for NCA and MCA
(P < 0.01; Table 1
). The effect of PAF receptor antagonist
TCV 309 was not significant for NCA and MCA. Each receptor antagonist
at the concentration of 10-5 mol/L completely inhibited
the neutrophil migration in response to LTB4 and PAF at the
concentration of 10-7 mol/L, respectively, but did not
show any inhibitory effects on FMLP and activated-serum-induced
neutrophil chemotaxis (data not shown).
|
The concentrations of LTB4 in the supernatant fluids in response to BK at the concentration of 100 µmol/L for 72 hours and control were 68.8 ± 12.4 pg/ml versus 55.4 ± 13.4 pg/ml (n = 6; P = 0.10). However, PAF in the supernatant fluids was not detected in response to BK stimulation (below 40 pg/ml).
Effects of Blocking Antibodies to IL-8, G-CSF, MCP-1, and TGF-ß on NCA and MCA in the Supernatant Fluids
Anti-IL-8 antibody blocked NCA by 40%, and anti-G-CSF antibody
attenuated NCA up to 50%. Anti-MCP-1 antibody inhibited 50% of total
MCA, and anti-TGF-ß and anti-G-CSF antibodies inhibited 10% of MCA
(Figure 6, A and B)
. These blocking
antibodies blocked each corresponding molecular weight peak separated
by molecular sieve column chromatography, respectively (data not
shown). The nonimmune IgG was used to evaluate the effect of
nonspecific antibody. Nonimmune IgG did not attenuate the NCA and MCA
in the same BK-conditioned medium.
|
The measurement of chemotactic cytokines by ELISA revealed that BK
at the concentration of 100 µmol/L for 72 hours of incubation
significantly stimulated the release of IL-8, G-CSF, MCP-1, and TGF-ß
from A549 cells (Table 2)
. In contrast
RANTES, MIP-1, and GM-CSF were not detected in A549 cell supernatant
fluids in response to BK and in the control condition. BK also
stimulated the release of IL-6 (Table 2)
.
|
. All chemokines showed
time-dependent increases.
|
Both BKB1 and BKB2 receptor antagonists significantly inhibited
the release of NCA and MCA equally harvested after 72 hours of
incubation (Figure 8, A and B)
. The
individual chemokines, ie, IL-8, MCP-1, and G-CSF, but not TGF-ß,
were inhibited significantly by BKB1 and BKB2 receptor antagonists
(Figure 9, A–D)
.
|
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The identification of NCA and MCA is not complete. It is reported that
ATII cells have the potential to release IL-8,15,20
MCP-1,23
and IL-621
in response to TNF-,
IL-1ß, and asbestos stimulation. In the present study, the blocking
antibody to IL-8, G-CSF, MCP-1, and TGF-ß attenuated the chemotactic
activity, and BK significantly stimulated the release of IL-8, G-CSF,
MCP-1, and TGF-ß from A549 cells. Although the highest molecular
weight peaks of MCA were undetermined, these data suggest that these
cytokines may be predominantly responsible for the NCA and MCA.
Although the releasing potential of IL-6, G-CSF, IL-8, MCP-1, and
TGF-ß from A549 cells by BK was less than that observed by TNF-
and IL-1 stimulation (unpublished data), the release of NCA and MCA was
increased three- to fourfold compared with the constitutive release of
chemotactic activity. The chemotactic potential of released activity
from A549 cells was more than the released activity from
106
alveolar macrophages per culture dish in response to
endotoxin (unpublished data). Thus, BK may contribute to the
recruitment of inflammatory cells into the alveolar space by
stimulating ATII cells.
BK has been reported to have several potent effects on airway functions, many of which are thought to be mediated via the BKB2 receptor. The existence of the BKB2 receptor has been mapped out in humans and guinea pig lungs by autoradiography with [3H]BK.35 BKB1 receptor ligands do not displace [3H]BK binding in trachea and lung, indicating the absence of BKB1 receptors and the presence of BKB2 receptors in the healthy lung.36 However, the BKB1 receptor antagonist Des-Arg9-[Leu8]-BK significantly inhibited airway hyperresponsiveness and neutrophilia induced by antigen challenge.37 Although the BK receptor on A549 cells is not identified, the present study suggests that both BKB1 and BKB2 receptors are concerned with the release of NCA and MCA. Thus, the receptor responsible for the release of IL-8, G-CSF, and MCP-1 may involve both BKB1 and BKB2 receptors.
IL-6 is a cytokine involved in the regulation of the immune response and inflammation. IL-6 modulates proliferation of lymphoid and nonlymphoid cells.38 Although IL-6 is usually thought of as a pro-inflammatory cytokine, it has been suggested that IL-6 may act as an inhibitor of local acute inflammation, particularly in the lung.39 However, the concentration of IL-6 is elevated in patients with various lung diseases.40,41 Although alveolar macrophages are certainly involved in the generation of alveolar IL-6, as they are known as potent producers of IL-6,42 the possible contribution to IL-6 production by ATII cells in response to BK may support the regulation of the alveolar IL-6 production.
TGF-ß induces monocyte chemotaxis at concentrations from 0.1 to 10 pg/ml.43 At higher concentrations, the chemotactic response of monocytes declined. Wakefield and co-workers reported that the biologically inactive form of TGF-ß, which constitutes more than 98% of autocrine TGF-ß secreted by all of 12 different cell types assayed, was shown to be unable to bind to the receptor without previous activation.44 Although the concentrations of TGF-ß were far above the monocyte chemotactic range, ie, 500 to 700 pg/ml in the present study, the active form of TGF-ß was less than 2%. This may account for the concentration discrepancy of TGF-ß-induced monocyte chemotaxis.
Wang and co-workers reported the chemotactic activity of recombinant human G-CSF for neutrophils and monocytes.45 G-CSF was active in inducing neutrophil migration at concentrations more than 10 to 100 U/ml (7 to 70 ng/ml). The concentration of G-CSF in the supernatant fluids released from A549 cells was relatively low. However, the blocking antibody of G-CSF inhibited chemotactic responses of neutrophils by 40% and monocytes up to 10%. The discrepancy of G-CSF concentration for neutrophil migration compared with the present data might be due to the differences of neutrophil preparation, because human recombinant G-CSF induced neutrophil migration at 10 to 1000 pg/ml in our laboratory. The concentration of G-CSF in the A549 cell supernatant fluids induced by BK reached this chemotactic concentration.
In conclusion, BK induced the release of NCA and MCA from A549 cells. The released NCA and MCA in response to BK were both chemotactic and chemokinetic. Although the released activity was heterogeneous in its character, LTB4 receptor antagonist and blocking antibodies to IL-8, G-CSF, MCP-1, and TGF-ß significantly inhibited the chemotactic response, and the releases of IL-6, IL-8, G-CSF, MCP-1, and TGF-ß were significantly augmented in response to BK stimulation. These data suggest that BK may stimulate ATII cells to release NCA, MCA, and inflammatory cytokines and may modulate lung inflammation in the lung diseases.
|
Footnotes |
|---|
Accepted for publication August 22, 1998.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  P. G. Arndt, S. K. Young, K. R. Poch, J. A. Nick, S. Falk, R. W. Schrier, and G. S. Worthen Systemic Inhibition of the Angiotensin-Converting Enzyme Limits Lipopolysaccharide-Induced Lung Neutrophil Recruitment through Both Bradykinin and Angiotensin II-Regulated Pathways J. Immunol., November 15, 2006; 177(10): 7233 - 7241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hammerschmidt, H. Kuhn, U. Sack, A. Schlenska, C. Gessner, A. Gillissen, and H. Wirtz Mechanical Stretch Alters Alveolar Type II Cell Mediator Release toward a Proinflammatory Pattern Am. J. Respir. Cell Mol. Biol., August 1, 2005; 33(2): 203 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Ebrahimian, R. Tamarat, M. Clergue, M. Duriez, B. I. Levy, and J.-S. Silvestre Dual Effect of Angiotensin-Converting Enzyme Inhibition on Angiogenesis in Type 1 Diabetic Mice Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 65 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Souza, E. S. L. Lomez, V. Pinho, J. B. Pesquero, M. Bader, J. L. Pesquero, and M. M. Teixeira Role of Bradykinin B2 and B1 Receptors in the Local, Remote, and Systemic Inflammatory Responses That Follow Intestinal Ischemia and Reperfusion Injury J. Immunol., February 15, 2004; 172(4): 2542 - 2548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Pagano, Y. Donati, I. Metrailler, and C. Barazzone Argiroffo Mitochondrial cytochrome c release is a key event in hyperoxia-induced lung injury: protection by cyclosporin A Am J Physiol Lung Cell Mol Physiol, February 1, 2004; 286(2): L275 - L283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Koyama, E. Sato, A. Tsukadaira, M. Haniuda, H. Numanami, M. Kurai, S. Nagai, and T. Izumi Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro Eur. Respir. J., December 1, 2002; 20(6): 1449 - 1456. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. C. Rodgers, L. Pang, E. Holland, L. Corbett, S. Range, and A. J. Knox Bradykinin increases IL-8 generation in airway epithelial cells via COX-2-derived prostanoids Am J Physiol Lung Cell Mol Physiol, September 1, 2002; 283(3): L612 - L618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yu, X. Zheng, H. Witschi, and K. E. Pinkerton The Role of Interleukin-6 in Pulmonary Inflammation and Injury Induced by Exposure to Environmental Air Pollutants Toxicol. Sci., August 1, 2002; 68(2): 488 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Takamizawa, S. Koyama, E. Sato, T. Masubuchi, K. Kubo, M. Sekiguchi, S. Nagai, and T. Izumi Bleomycin Stimulates Lung Fibroblasts to Release Neutrophil and Monocyte Chemotactic Activity J. Immunol., May 15, 1999; 162(10): 6200 - 6208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Silvestre, S. Bergaya, R. Tamarat, M. Duriez, C. M. Boulanger, and B. I. Levy Proangiogenic Effect of Angiotensin-Converting Enzyme Inhibition Is Mediated by the Bradykinin B2 Receptor Pathway Circ. Res., October 12, 2001; 89(8): 678 - 683. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
) from A549 cell
monolayers (n = 8). 
,
baseline release of neutrophil chemotactic activity. Values are
expressed as means ± SE. *P < 0.01 compared with
supernatant fluids without incubation. 
P
0.01 compared with supernatant fluids without BK stimulation.
, molecular
profiles of monocyte chemotactic activity under the unstimulated state.
These data are the representative data of four experiments.
